GISEL:Registry of Breast Cancer Patients Treated With ECT

CompletedOBSERVATIONAL
Enrollment

205

Participants

Timeline

Start Date

April 22, 2016

Primary Completion Date

October 21, 2021

Study Completion Date

December 10, 2022

Conditions
Breast CancerBreast Cancer MetastaticBreast Cancer Recurrent
Interventions
DEVICE

Electrochemotherapy (ECT)

Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.

DRUG

Bleomycin

Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane

Trial Locations (1)

35128

Veneto Institute of Oncology IRCCS, Padua

All Listed Sponsors
lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT06683404 - GISEL:Registry of Breast Cancer Patients Treated With ECT | Biotech Hunter | Biotech Hunter